Amphastar Pharmaceuticals reports Q2 net revenues of $174.4 million and net income of $31.0 million

Reuters

2025/11/21

<a href="https://laohu8.com/S/AMPH">Amphastar Pharmaceuticals</a> reports <a href="https://laohu8.com/S/QTWO">Q2</a> net revenues of $174.4 million and net income of $31.0 million

Amphastar Pharmaceuticals Inc. reported net product revenues of $174.4 million for the three months ended June 30, 2025, compared to $179.4 million for the same period in 2024. Total net revenues for the quarter were $174.4 million, down from $182.4 million in the prior year period. Gross profit was $86.5 million, compared to $95.2 million for the second quarter of 2024. For the six months ended June 30, 2025, net product revenues were $344.9 million, compared to $337.0 million for the same period in 2024, while total net revenues were $344.9 million, down from $354.2 million. Cost of revenues for the quarter was $87.9 million, compared to $87.2 million a year earlier. Operating expenses for the quarter included $10.2 million in selling, distribution, and marketing, $14.0 million in general and administrative, and $20.1 million in research and development. The company noted there is no guarantee that its sales strategies will be successful or that significant sales of BAQSIMI will continue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2585150860"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585150860\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585150860?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 05:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585150860","market":"us","top_or_hot":-1,"title":"Amphastar Pharmaceuticals reports Q2 net revenues of $174.4 million and net income of $31.0 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AMPH\">Amphastar Pharmaceuticals</a> reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net revenues of $174.4 million and net income of $31.0 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amphastar Pharmaceuticals Inc. reported net product revenues of $174.4 million for the three months ended June 30, 2025, compared to $179.4 million for the same period in 2024. Total net revenues for the quarter were $174.4 million, down from $182.4 million in the prior year period. Gross profit was $86.5 million, compared to $95.2 million for the second quarter of 2024. For the six months ended June 30, 2025, net product revenues were $344.9 million, compared to $337.0 million for the same period in 2024, while total net revenues were $344.9 million, down from $354.2 million. Cost of revenues for the quarter was $87.9 million, compared to $87.2 million a year earlier. Operating expenses for the quarter included $10.2 million in selling, distribution, and marketing, $14.0 million in general and administrative, and $20.1 million in research and development. The company noted there is no guarantee that its sales strategies will be successful or that significant sales of BAQSIMI will continue.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amphastar Pharmaceuticals reports Q2 net revenues of $174.4 million and net income of $31.0 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmphastar Pharmaceuticals reports Q2 net revenues of $174.4 million and net income of $31.0 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-21 05:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AMPH\">Amphastar Pharmaceuticals</a> reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net revenues of $174.4 million and net income of $31.0 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amphastar Pharmaceuticals Inc. reported net product revenues of $174.4 million for the three months ended June 30, 2025, compared to $179.4 million for the same period in 2024. Total net revenues for the quarter were $174.4 million, down from $182.4 million in the prior year period. Gross profit was $86.5 million, compared to $95.2 million for the second quarter of 2024. For the six months ended June 30, 2025, net product revenues were $344.9 million, compared to $337.0 million for the same period in 2024, while total net revenues were $344.9 million, down from $354.2 million. Cost of revenues for the quarter was $87.9 million, compared to $87.2 million a year earlier. Operating expenses for the quarter included $10.2 million in selling, distribution, and marketing, $14.0 million in general and administrative, and $20.1 million in research and development. The company noted there is no guarantee that its sales strategies will be successful or that significant sales of BAQSIMI will continue.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMPH","symbol_name":"Amphastar Pharmaceuticals","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL18cJcb:1","article_id":"2585150860","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585150860","pubTimestamp":1763673160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Amphastar Pharmaceuticals Inc. reported net product revenues of $174.4 million for the three months ended June 30, 2025, compared to $179.4 million for the same period in 2024. Total net revenues for the quarter were $174.4 million, down from $182.4 million in the prior year period. Gross profit was $86.5 million, compared to $95.2 million for the second quarter of 2024. For the six months ended June 30, 2025, net product revenues were $344.9 million, compared to $337.0 million for the same period in 2024, while total net revenues were $344.9 million, down from $354.2 million. Cost of revenues for the quarter was $87.9 million, compared to $87.2 million a year earlier. Operating expenses for the quarter included $10.2 million in selling, distribution, and marketing, $14.0 million in general and administrative, and $20.1 million in research and development. The company noted there is no guarantee that its sales strategies will be successful or that significant sales of BAQSIMI will cont","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMPH":"Amphastar Pharmaceuticals","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4557":"大麻股","BK4007":"制药"},"translate_title":"Amphastar Pharmaceuticals报告第二季度净收入为1.744亿美元，净利润为3100万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMPH":0.9},"content_text":"Amphastar Pharmaceuticals reports Q2 net revenues of $174.4 million and net income of $31.0 million\n    \n\n        Amphastar Pharmaceuticals Inc. reported net product revenues of $174.4 million for the three months ended June 30, 2025, compared to $179.4 million for the same period in 2024. Total net revenues for the quarter were $174.4 million, down from $182.4 million in the prior year period. Gross profit was $86.5 million, compared to $95.2 million for the second quarter of 2024. For the six months ended June 30, 2025, net product revenues were $344.9 million, compared to $337.0 million for the same period in 2024, while total net revenues were $344.9 million, down from $354.2 million. Cost of revenues for the quarter was $87.9 million, compared to $87.2 million a year earlier. Operating expenses for the quarter included $10.2 million in selling, distribution, and marketing, $14.0 million in general and administrative, and $20.1 million in research and development. The company noted there is no guarantee that its sales strategies will be successful or that significant sales of BAQSIMI will continue.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}